熊江辉用网络药理学研究药物组合中药研究潜在应用.ppt

内容总结 In silico Genetic Network Models for Pre-clinical Drug Prioritization。Gene Signature for。Perturbation Index (PI)。For each gene。Gene-Gene。‘Standard Agent Database’。Gene list AB。Validity of Bortezomib-Paclitaxel。Prediction-based strategy。The Inter-Module Network 第三十一页，共三十一页。 * * * * * * * * * * In silico Genetic Network Models for Pre-clinical Drug Prioritization Section 2-1: Genomics, Proteomics and Metabolomics in Drug Discovery and Target Validation 第一页，共三十一页。 Network pharmacology 第二页，共三十一页。 The information to deliver Network could be drug target Jianghui Xiong etc., Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. PloS ONE 2010 “For more than a decade, scientists in systems biology have promised that real breakthrough in genetic medicine will come when we stop mapping individual genes to phenotypes and instead start looking at interacting networks. Yet, not much has happened. The field is still struggling to define relevant networks and to interpret data in terms of those networks. The paper by Xiong et al adds considerably to the progress of network-based genetic medicine. It is highly relevant, original and interesting.” 第三页，共三十一页。 Oncology Drug DevelopmentOne of most challenging scientific problems What’s wrong with our cancer models? NATURE REVIEWS DRUG DISCOVERY, 2005 第四页，共三十一页。 The current models used for pre-clinical drug testing Do NOT accurately predict how new treatments will act in clinical trials Heterogeneity in patient populations Unpredictable physiology What’s wrong with our cancer models? NATURE REVIEWS DRUG DISCOVERY, 2005 What’s wrong with our Disease Models Drug Discov Today Dis Models, 2008 ? 第五页，共三十一页。 Hypothesis Considering gene networks associated with cancer outcome in heterogeneous patient populations The difficulty of identify effective cancer cures (as evidenced by drug resistance) may be a consequence of the robustness of this network Network (robustness) as drug targ